2012 Annual Meeting | Neuro-oncology: Primary Brain Tumors

Date Monday 04/23/12

Time 09:00 AM - 01:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type AM Half-Day Course

Director(s) Jaishri Blakeley, MD, FAAN

Topic(s)

Learning Objectives Participants should be familiar with the current recommendations for the diagnosis and treatment of primary brain tumors in adults. This includes identifying most appropriate diagnostic techniques, incorporating prognostic and predictive factors into treatment decisions, and current recommendations for systemic therapies. Participants should gain an evidence base for the management of seizures, venous thrombosis, infection, and cognitive symptoms during and after brain tumor treatment, and learn strategies to enhance quality of life for patients with long-term complications and sequelae of tumor therapy.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Interpersonal and Communication Skills, Professionalism, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Recommended Audience Other, Trainee, General Neurologist, Specialist Neurologist, Non-neurologist

Teaching Styles Didactic, Interactive, Audience Participation

Program Evaluations

Event Timeline
09:00 AM - 09:10 AM		Introduction and Goals Jaishri Blakeley, MD, FAAN
09:10 AM - 09:50 AM		When Benign Is Not Benign—Meningiomas and Other “Benign” Brain Tumors Marc Chamberlain, MD
09:50 AM - 10:30 AM		Taming a Beast: Emerging Approaches for Management of Gliomas Jaishri Blakeley, MD, FAAN
10:30 AM - 10:45 AM		Break
10:45 AM - 11:25 AM		Primary CNS Lymphoma Erin M. Dunbar, MD
11:25 AM - 12:05 PM		Managing Complications of Primary Brain Tumors: the Role of the Neurologist Scott R. Plotkin, MD, PhD, FAAN
12:05 PM - 12:15 PM		Break
12:15 PM - 01:00 PM		Putting It All Together: Case Conference Jaishri Blakeley, MD, FAAN, Marc Chamberlain, MD, Erin M. Dunbar, MD, Scott R. Plotkin, MD, PhD, FAAN

Faculty Disclosures
Jaishri Blakeley, MD, FAAN	Dr. Blakeley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Springworks Therapeutics.
Marc Chamberlain, MD	No disclosure on file
Erin M. Dunbar, MD	Dr. Dunbar has nothing to disclose.
Scott R. Plotkin, MD, PhD, FAAN	Dr. Plotkin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for NFlection Therapeutics. Dr. Plotkin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Akouos. Dr. Plotkin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SonALAsense. Dr. Plotkin has stock in NFlection Therapeutics. Dr. Plotkin has stock in NF2 Therapeutics. Dr. Plotkin has stock in SonALAsense. Dr. Plotkin has received research support from Children's Tumor Foundation. Dr. Plotkin has received research support from Department of Defense. Dr. Plotkin has received research support from National Institutes of Health. Dr. Plotkin has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��